Business
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist
About this update from Silexion Therapeutics Corp
[{"type":"text","content":"Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist Silexion as it advances its RNAi platform and next-generation therapies targeting KRAS mutations\nCayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company’s audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing novel cancer therapies from discovery to FDA approval. Ilan Hadar, Chairman and CEO of Silexion, commented: “We are thrilled to welcome Prof. Peled to our Board of Directors. His unparalleled expertise in cancer biology, stem cell mobilization, and therapeutic development will be invaluable as Silexion continues to advance its pipeline of RNAi-based therapies for difficult-to-treat cancers. Prof. Peled’s track record in translating innovative science into impactful clinical outcomes aligns perfectly with our mission to address unmet needs in oncology.” “I am excited to join Silexion at such a pivotal time in its journey,” said Prof. Amnon Peled. “The Company’s RNAi platform holds tremendous promise for addressing some of the most challenging oncology indications. I look forward to contributing my expertise to help advance Silexion’s innovative pipeline and drive meaningful impact for patients.” Prof. Peled’s appointment reinforces Silexion’s commitment to scientific and strategic excellence as it advances its RNAi platform and next-generation therapies targeting KRAS mutations. His extensive experience in clinical development and regulatory pathways will contribute to Silexion’s mission of delivering innovative solutions for patients facing the most challenging cancers. Prof. Peled’s appointment also fills its current board vacancy, ensuring Silexion remains in compliance with Nasdaq’s listing requir...